310 related articles for article (PubMed ID: 31734589)
1. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.
David S; Tan J; Savas P; Bressel M; Kelly D; Foroudi F; Loi S; Siva S
Breast; 2020 Feb; 49():55-62. PubMed ID: 31734589
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
4. Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience.
Li MP; Kelly D; Tan J; Siva S; Kron T; David S
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):580-585. PubMed ID: 32588550
[TBL] [Abstract][Full Text] [Related]
5. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
Moyer CL; Phillips R; Deek MP; Radwan N; Ross AE; Antonarakis ES; Reyes D; Wright J; Terezakis SA; Song DY; DeVille C; Walsh PC; DeWeese TL; Carducci M; Schaeffer EM; Pienta KJ; Eisenberger M; Tran PT
World J Urol; 2019 Dec; 37(12):2623-2629. PubMed ID: 30191396
[TBL] [Abstract][Full Text] [Related]
7. Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.
Wijetunga NA; Dos Anjos CH; Zhi WI; Robson M; Tsai CJ; Yamada Y; Dover L; Gillespie EF; Xu AJ; Yang JT
Cancer Med; 2021 Aug; 10(15):5163-5174. PubMed ID: 34159748
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial.
Mercier C; Claessens M; Buys MSc A; Gryshkevych S; Billiet C; Joye I; Van Laere S; Vermeulen P; Meijnders P; Löfman F; Poortmans P; Dirix L; Verellen D; Dirix P
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1195-1205. PubMed ID: 33307151
[TBL] [Abstract][Full Text] [Related]
9. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
[TBL] [Abstract][Full Text] [Related]
11. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
12. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
16. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
17. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
Ost P; Jereczek-Fossa BA; As NV; Zilli T; Muacevic A; Olivier K; Henderson D; Casamassima F; Orecchia R; Surgo A; Brown L; Tree A; Miralbell R; De Meerleer G
Eur Urol; 2016 Jan; 69(1):9-12. PubMed ID: 26189689
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
[TBL] [Abstract][Full Text] [Related]
19. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
[TBL] [Abstract][Full Text] [Related]
20. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
